Mustang Bio rises after FDA orphan drug status for MB-101

9 hours ago 2
Dendritic Cell activate T cells, trigger immune responses, they are responsible of cells protection of the body.

Design Cells/iStock via Getty Images

Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the compay said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and glioblastoma, types of brain tumour.

The stock

Recommended For You

More Trending News

Read Entire Article